Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)
NCT ID: NCT02484482
Last Updated: 2015-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
45 participants
INTERVENTIONAL
2015-06-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Fasting→Standard Meal→High Fat Meal
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Group 2
CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Standard Meal→High Fat Meal→Fasting
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Group 3
CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
High Fat Meal→Fasting→Standard Meal
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Group 4
CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Fasting→High Fat Meal→Standard Meal
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Group 5
CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
Standard Meal→Fasting→High Fat Meal
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Group 6
CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
High Fat Meal→Standard Meal→Fasting
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-519 200mg / Fasting, Standard Meal, High Fat Meal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight more than 55kg in male, 50kg in female
3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)
4. If female, must include more than one among the items
* The menopause(there is no natural menses for at least 2 years)
* Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition)
5. If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms and do not sperm donation until two months during clinical trials and after the final dosage of investigational products
6. Those who fully understand about this clinical trials after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent
Exclusion Criteria
2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)
3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of drugs or additives.
4. An impossible one who participates in clinical trial including screening tests (medical history taking, BP, 12-lead ECG, physical examination, blood\&urine laboratory test result) before 28 days the taking investigational products.
5. Defined by the following laboratory parameters
* AST(Aspartate aminotransferase), ALT(Alanine aminotransferase)\>1.25\* upper limit of normal range
* Total bilirubin\>1.5\* upper limit of normal range
* CPK(Creatine phosphokinase)\>1.5\* upper limit of normal range
* eGFR(Estimated Glomerular Filtration Rate, using by MDRD(Modification of Diet in Renal Disease) method)\<60 mL/min/1.73m2
6. Sitting SBP(Systolic Blood Pressure )\>150 mmHg or \<90 mmHg, sitting DBP(Diastolic Blood Pressure )\>100 mmHg or 50 mmHg , after 5 minutes break.
7. Drug abuse or have a history of drug abuse shows a positive for urine drug test.
8. Pregnant or lactating women.
9. A heavy caffeine consumer(caffeine\>5 cups/day), alcohol consumer(alcohol\>210g/week), or smoker(cigarette\>10 cigarettes/day)
10. Subject takes ethical drug or herbal medicine within 14 days, OTC(Over The Counter Drug) within 7 days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of subjects
11. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates etc.) within 30days.
12. Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1 liter per a day or more within 7days before the beginning of study treatment)
13. Subject who treated with any investigational drugs within 90 days before the beginning of study treatment.
14. Previously donate whole blood within 60 days or component blood within 30days.
15. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
16. Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
148FDI15009
Identifier Type: -
Identifier Source: org_study_id